The FDA slaps a hold on uniQure's hemophilia B gene therapy as researchers explore a case of liver cancer in latest setback for a booming field

In the latest sampling of a setback in the stumble-prone gene therapy field, uniQure today announced that the FDA has slapped a clinical hold on …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The FDA slaps a hold on uniQure's he­mo­phil­ia B gene ther­a­py as re­searchers ex­plore a case of liv­er can­cer in lat­est set­back for a boom­ing field